[PDF] tumor metabolic volume by 18f?fDG?pet as a prognostic predictor of

View - Download tumor metabolic volume by 18f?fDG?pet as a prognostic predictor of

Previous PDF

Next PDF

Scientific Repo

R t

S | (2020) 10:14990 |

www.nature.com/scientificreports tumor metabolic volume by f f DG- pet as a prognostic pembrolizumab for n S c

Lc patients

o u

Yamaguchi

-glucose f-f DG positron ) on f- cellshavebeen reported 1-3

PD-L1expression

level

4,5.Asa?rst-linetreatmentinpatientswithPD-L1expression≥ 50%,however,itremains

patientswithPD-L1expression ≥ 50% 2

2-Deoxy-2-[

18

F]?uoro-

d-glucose( 18 18

F-FDGonPETsuggestsitsuseasopen

Department

Vol:.(1234567890)

Scientific Repo

R t

S | (2020) 10:14990 |

www.nature.com/scientificreports/ NSCLC 6-8 .A uptakevalues (SUV max )inlung cancer 8 ofanti-PD-1antibodyby 18

F-FDGPET

9 andthecloserelationshipbetween 18

F-FDGuptakeandPD-L1expres

sionwithintumorcellsby immunohistochemistry 10 12 13 .Iftheaccu mulationof 18 18 therapyasapredictivemarker;however,fewerthanhalfofpatientswithPD-L1expression ≥ 50%showedan disease 2 .Morespeci?cpredictivemarkers predictivemarkersofpembrolizumabinNSCLCpatientswithPD-L1expression ≥ 50%. linepembrolizumabmonotherapyinpatientswithuntreatedadvancedNSCLCwithPD-L1expression ≥ 50%.

Results

?isstudyenrolledatotalof48patients(n males 39,n
females 9; medianage =69years;agerange47-86 years).?eirdemographicsaccordingtoFDGuptakearelistedinTable 1. Table 1.

Patient'sdemographicsaccordingto

18

F-FDGuptake.

PS performancestatus,

ACadenocarcinoma,

ILD interstitiallungdisease, BMI bodymassindex, NLR neutrophiltolymphocyteratio, CRP

C-reactive

protein, uptakevalue, PD-L1 programmeddeathligand-1,

Response*

signi?cance.

VariablesTotal patientsMTVTLGSUVmax

N

48High N = 12Low N = 36p valueHigh N = 21High N = 27p valueHigh N = 20Low N = 28p value

Age 69/>

69 years25/237/518/180.7410/1115/120.779/1116/120.55

Gender

Male/female

Smoking

Yes/no

PS

0-1/2-3

30/186/624/120.328/1322/5 < 0.0111/919/90.38

Histology

AC/non-AC

23/253/920/160.095/1618/9 < 0.016/1417/110.04

Distantmetastases

Yes/no

37/1112/025/110.0421/016/11 < 0.0117/320/80.31

ILD

Previousradiation

BMI

High/low

NLR

High/low

CRP 1.0/> 1.0

21/271/1120/16 < 0.013/189/180.187/1314/140.38

Response*

Responder/non-responder

Brainmetastases

Yes/no

Bonemetastasis

Yes/no17/318/49/270.0113/84/23 < 0.0112/85/23 < 0.01

Livermetastasis

Yes/no6/423/93/330.156/150/27 < 0.013/173/250.68

PD-L1 75(%)

25/233/922/140.0416/59/18 < 0.0114/611/170.04

Vol.:(0123456789)

Scientific Repo

R t

S | (2020) 10:14990 |

www.nature.com/scientificreports/

50-75%and ≥ 75%,respectively.

?emedianvaluesforMTV,TLG,and SUV max beforepembrolizumabtreatmentwere112 cm 3 ,513g cm 3 /mL, and11,respectively.?eoptimal 18

F-FDGuptakecut-o?sforMTV,TLG,andSUV

max todi?erentiateresponders cm 3 (range9-1,401,sensitivity:91%,speci?city:32%),697g cm 3 SUV max .?emedianperiodbetween 18 F-FDG PETandinitiationofpembrolizumabwas27 days,rangingfrom4to77 days.?emedianadministrationof pembrolizumabdisplayed5cycles(range1-29cycles),andthemedianfollow-upperiodwas346 days,ranging from30to884 days.

Table 1showsthepatients'demographicsaccordingto

18

F-FDGuptake.Assessmentof

18

F-FDGuptake

SUV max SUV max =0.84,p<0.001)andTLG(γ=0.81,p<0.001). ?eoverallmedianPFSandmedianOSwere7.1and18.6 months,

36.5-65.7%).Analysisof

18 highandlowTLG,andhighandlow SUV max of30%(3/10)and57%(20/35)(p =0.16),42%(8/19)and57% (15/26)( p tus(Table 2).Highbodymassindex(BMI)wasstatisticallyassociatedwithresponders.?eanalysisonthe Table 2. adenocarcinoma, ILD interstitiallungdisease, BMI bodymassindex, NLR neutrophiltolymphocyteratio, CRP

C-reactiveprotein,

standardizeduptakevalue, PD-L1

VariablesTotal patientsResponderNon-responder

p valueN = 45N = 23N = 22 Age 69/>

69 years24/2113/1011/110.76

Gender

Male/female

36/920/316/60.28

Smoking

Yes/no

41/420/321/10.61

PS

0-1/2-3

29/1615/814/8>0.99

Histology

AC/non-AC

22/2310/1312/100.76

Distantmeta

Yes/no

34/1116/718/40.49

ILD

Yes/no15/306/179/130.35

Previousradiation

Yes/no14/315/189/130.21

BMI

High/low

20/2514/96/160.03

NLR

High/low

22/2312/1110/120.76

CRP 1.0/> 1.0

20/2512/118/140.37

SUVmax

High/low

19/268/1511/110.37

MTV

High/low

10/353/207/150.16

TLG

High/low19/268/1511/110.37

PD-L1 75/>
quotesdbs_dbs26.pdfusesText_32

[PDF] BODY PAINTING

[PDF] body painting - Make Up For Ever - France

[PDF] Body Part Practice - Anciens Et Réunions

[PDF] Body Percussion

[PDF] Body Pillow - Grany Confort Medical - Canapés Et Fauteuils

[PDF] Body Rox - Anciens Et Réunions

[PDF] Body Rox - USANA Supplements - Anciens Et Réunions

[PDF] body scrub

[PDF] BODY SCULPT : Le body sculpt est une - Marines

[PDF] Body Sculpt FC - AT PumP RPM RPM Boxe Zumba Gym Zumba - Anciens Et Réunions

[PDF] Body Shop CREOLA

[PDF] Body Talk

[PDF] Body Tonie Fitness: Prestations musclées à prix

[PDF] Body weAther Body mINd CeNterINg kAtsugeN uNdo - France

[PDF] BODY With easy-to-read, step-by-step instructions and - Email